Amarin Corporation plc. (NASDAQ:AMRN) is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa(R) (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa(R) visit http://www.vascepa.com
